| DIRECT COMPETITOR COMPARISON | |
| NVAX | Pvt1 | MRK | NVS | Industry | | Market Cap: | 191.65M | N/A | 76.92B | 121.69B | 107.08M | | Employees: | 69 | N/A | 55,200 | 99,000 | 59 | | Qtrly Rev Growth (yoy): | 3.60% | N/A | 1.80% | 2.40% | 19.70% | | Revenue (ttm): | 321.00K | N/A | 23.37B | 42.31B | 13.84M | | Gross Margin (ttm): | 100.00% | N/A | 76.36% | 72.61% | 66.58% | | EBITDA (ttm): | -30.39M | N/A | 7.81B | 11.24B | -12.25M | | Oper Margins (ttm): | -9,845.48% | N/A | 26.63% | 21.50% | -158.08% | | Net Income (ttm): | -34.99M | N/A | 8.05B | 7.59B | N/A | | EPS (ttm): | -0.430 | N/A | 3.808 | 3.34 | -0.31 | | P/E (ttm): | N/A | N/A | 9.58 | 16.04 | 17.08 | | PEG (5 yr expected): | N/A | N/A | 2.44 | 2.97 | 1.15 | | P/S (ttm): | 608.70 | N/A | 3.30 | 2.85 | 9.82 |
|
| BIOTECHNOLOGY COMPANIES RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Amgen Inc. | AMGN | 57.21 | -0.44% | 56.92B | 12.69 | | Genentech, Inc. | Private - View Profile | | Biogen Idec Inc. | BIIB | 54.09 | 2.37% | 15.64B | 18.10 | | Genzyme Corp. | GENZ | 54.87 | 0.70% | 14.56B | 31.28 | | Merck Serono S.A. | Private - View Profile | | Gilead Sciences Inc. | GILD | 46.30 | 0.46% | 41.66B | 16.41 | | MedImmune, Inc. | Private - View Profile | | Life Technologies Corporation | LIFE | 47.82 | 0.84% | 8.54B | 59.92 | | Teva Pharmaceutical Industries Limited | TEVA | 57.10 | 0.32% | 50.31B | 52.24 | | Sandoz International GmbH | Private - View Profile |
|
| GENERIC DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Watson Pharmaceuticals Inc. | WPI | 38.10 | 1.09% | 4.04B | 19.64 | | King Pharmaceuticals Inc. | KG | 11.44 | 1.24% | 2.84B | N/A | | Ranbaxy Laboratories Limited | Private - View Profile | | Mylan, Inc. | MYL | 17.68 | -0.45% | 5.40B | 108.47 | | Pfizer Inc. | PFE | 17.88 | 0.22% | 144.28B | 14.85 | | Johnson & Johnson | JNJ | 62.76 | 0.63% | 173.16B | 14.27 | | GlaxoSmithKline plc | GSK | 38.47 | 0.92% | 97.52B | 12.91 | | Sanofi-Aventis | SNY | 36.29 | 1.06% | 94.76B | N/A | | Novartis AG | NVS | 53.58 | 0.94% | 121.69B | 16.04 | | RHHBY.PK | 41.50 | 1.39% | N/A | N/A |
|
| DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | AstraZeneca plc | AZN | 44.11 | 2.27% | 64.00B | 8.50 | | Abbott Laboratories | ABT | 53.35 | 0.00% | 82.52B | 14.44 | | Bristol-Myers Squibb Company | BMY | 24.25 | 1.21% | 48.04B | 4.51 |
|
| NEWS ON DIRECT COMPETITORS | |
|
|
|